miRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cells
- PMID: 24866595
- DOI: 10.1016/j.juro.2014.05.094
miRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cells
Abstract
Purpose: We investigated the potential functions of miR-34a in CD44 transcriptional complexes in renal cell carcinoma.
Materials and methods: We detected miR-34a expression by quantitative real-time polymerase chain reaction. Oligonucleotides were used to over express miR-34a. Cell proliferation and xenograft assays, colony formation and flow cytometry were done to examine effects on cancer cell proliferation in vitro and in vivo. Luciferase assay was performed to verify the precise target of miR-34a.
Results: Promoter methylation contributed to miR-34a loss in the ACHN, 786-O and SN12PM6 renal carcinoma cell lines. Ectopic over expression of miR-34a restrained cell growth, tube formation and migration/invasion, and significantly suppressed the growth of renal carcinoma xenografts and metastasis in nude mice. Dual luciferase assay revealed that CD44 was a direct target of miR-34a in renal cancer cells and CD44 knockdown by RNAi in renal cancer cells suppressed tumor progression. In contrast, CD44 ectopic expression partially reversed the antitumor effects of miR-34a in renal cancer cells.
Conclusions: Our findings indicate that miR-34a targets CD44 in renal cancer cells and suppresses renal cancer cell growth, tube formation and metastasis in vitro and in vivo. Thus, miR-34a may be a potential molecular target for novel therapeutic strategies for clear cell renal carcinoma.
Keywords: CD44 protein; MIRN34 microRNA; carcinogenesis; carcinoma; human; kidney; renal cell.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
MicroRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44.Mol Cell Biochem. 2018 Jun;443(1-2):139-149. doi: 10.1007/s11010-017-3218-3. Epub 2017 Nov 1. Mol Cell Biochem. 2018. PMID: 29094237
-
MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44.J Exp Clin Cancer Res. 2014 Dec 31;33(1):779. doi: 10.1186/s13046-014-0115-4. J Exp Clin Cancer Res. 2014. PMID: 25551284 Free PMC article.
-
miRNA-34a inhibits cell adhesion by targeting CD44 in human renal epithelial cells: implications for renal stone disease.Urolithiasis. 2020 Apr;48(2):109-116. doi: 10.1007/s00240-019-01155-9. Epub 2019 Sep 10. Urolithiasis. 2020. PMID: 31506763
-
Anti-tumor effects of miR-34a by regulating immune cells in the tumor microenvironment.Cancer Med. 2023 May;12(10):11602-11610. doi: 10.1002/cam4.5826. Epub 2023 Mar 23. Cancer Med. 2023. PMID: 36951490 Free PMC article. Review.
-
Multifunctional Roles of miR-34a in Cancer: A Review with the Emphasis on Head and Neck Squamous Cell Carcinoma and Thyroid Cancer with Clinical Implications.Diagnostics (Basel). 2020 Aug 5;10(8):563. doi: 10.3390/diagnostics10080563. Diagnostics (Basel). 2020. PMID: 32764498 Free PMC article. Review.
Cited by
-
Micall2 Is Responsible for the Malignancy of Clear Cell Renal Cell Carcinoma.Yonago Acta Med. 2023 Feb 20;66(1):171-179. doi: 10.33160/yam.2023.02.021. eCollection 2023 Feb. Yonago Acta Med. 2023. PMID: 36811029 Free PMC article.
-
MiR-935 Promotes Clear Cell Renal Cell Carcinoma Migration and Invasion by Targeting IREB2.Cancer Manag Res. 2019 Dec 30;11:10891-10900. doi: 10.2147/CMAR.S232380. eCollection 2019. Cancer Manag Res. 2019. Retraction in: Cancer Manag Res. 2020 Aug 17;12:7319. doi: 10.2147/CMAR.S275978. PMID: 31920398 Free PMC article. Retracted.
-
Expression Profiles and Clinical Significance of MicroRNAs in Papillary Renal Cell Carcinoma: A STROBE-Compliant Observational Study.Medicine (Baltimore). 2015 Apr;94(16):e767. doi: 10.1097/MD.0000000000000767. Medicine (Baltimore). 2015. PMID: 25906110 Free PMC article.
-
MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review).Oncol Rep. 2015 Apr;33(4):1571-8. doi: 10.3892/or.2015.3799. Epub 2015 Feb 13. Oncol Rep. 2015. PMID: 25682771 Free PMC article.
-
Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner.Oncotarget. 2015 Jun 30;6(18):16396-410. doi: 10.18632/oncotarget.3844. Oncotarget. 2015. PMID: 26036628 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous